Hikma raises guidance on back of doxycycline shortages
This article was originally published in Scrip
Executive Summary
Hikma has reported strong first half results ahead of analyst forecasts. Revenue increased by 20% to $638m. As a result, full year guidance has been raised to around 20% revenue growth (compared with 17% previously). Profit increased by 82% to $74m.